91.01
-0.13 (-0.14%)
| Previous Close | 91.14 |
| Open | 91.56 |
| Volume | 425,080 |
| Avg. Volume (3M) | 439,861 |
| Market Cap | 1,973,897,728 |
| Price / Earnings (Forward) | 13.05 |
| Price / Sales | 2.43 |
| Price / Book | 4.59 |
| 52 Weeks Range | |
| Earnings Date | 7 Nov 2025 |
| Profit Margin | -3.12% |
| Operating Margin (TTM) | 7.61% |
| Diluted EPS (TTM) | -1.18 |
| Quarterly Revenue Growth (YOY) | 43.40% |
| Quarterly Earnings Growth (YOY) | -13.90% |
| Total Debt/Equity (MRQ) | 142.03% |
| Current Ratio (MRQ) | 2.66 |
| Operating Cash Flow (TTM) | 80.74 M |
| Levered Free Cash Flow (TTM) | 39.80 M |
| Return on Assets (TTM) | 0.82% |
| Return on Equity (TTM) | -4.57% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | ANI Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | -5.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.60 |
|
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 11.08% |
| % Held by Institutions | 100.39% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 93.00 (HC Wainwright & Co., 2.19%) | Buy |
| Median | 85.00 (-6.60%) | |
| Low | 77.00 (Truist Securities, -15.39%) | Hold |
| Average | 85.00 (-6.60%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 83.18 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 11 Aug 2025 | 77.00 (-15.39%) | Hold | 84.88 |
| HC Wainwright & Co. | 08 Aug 2025 | 93.00 (2.19%) | Buy | 81.48 |
| 10 Jul 2025 | 84.00 (-7.70%) | Buy | 66.10 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DAVIS KRISTA | - | 91.01 | -1,763 | -160,451 |
| LEONARD MATTHEW J | - | 90.02 | -9,465 | -850,647 |
| PERA ANTONIO R | - | 90.62 | -5,421 | -491,251 |
| SHANMUGAM MUTHUSAMY | - | 90.88 | -100,000 | -9,089,554 |
| THOMA JEANNE | - | 89.71 | -21,540 | -1,932,353 |
| Aggregate Net Quantity | -138,189 | |||
| Aggregate Net Value ($) | -12,524,256 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 90.45 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LEONARD MATTHEW J | Director | 25 Aug 2025 | Sell (-) | 2,528 | 90.32 | 228,329 |
| DAVIS KRISTA | Officer | 22 Aug 2025 | Sell (-) | 1,763 | 91.01 | 160,451 |
| SHANMUGAM MUTHUSAMY | Officer | 21 Aug 2025 | Sell (-) | 52,988 | 91.14 | 4,829,326 |
| PERA ANTONIO R | Director | 20 Aug 2025 | Sell (-) | 5,421 | 90.62 | 491,251 |
| SHANMUGAM MUTHUSAMY | Officer | 20 Aug 2025 | Sell (-) | 47,012 | 90.62 | 4,260,227 |
| LEONARD MATTHEW J | Director | 18 Aug 2025 | Sell (-) | 6,937 | 89.71 | 622,318 |
| THOMA JEANNE | Director | 18 Aug 2025 | Sell (-) | 21,540 | 89.71 | 1,932,353 |
| Date | Type | Details |
|---|---|---|
| 25 Aug 2025 | Announcement | ANI Pharmaceuticals to Present at Upcoming Investor Conferences |
| 08 Aug 2025 | Announcement | ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance |
| 01 Aug 2025 | Announcement | ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET |
| 29 Jul 2025 | Announcement | Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals |
| 23 Jul 2025 | Announcement | ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME) |
| 02 Jul 2025 | Announcement | ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th |
| 12 Jun 2025 | Announcement | ANI Pharmaceuticals Announces Presentation of New Preclinical Data |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |